Regeneron is set to acquire the core assets of 23andMe for $256 million, absorbing its genome services, biobank, and research operations following the latter’s bankruptcy proceedings. The deal excludes 23andMe’s Lemonaid Health unit, which will be shut down.

This isn’t just a brand rescue—it’s a bold move to expand Regeneron’s footprint in population-scale genomics. With 80% of 23andMe users consenting to research participation, Regeneron gains access to a vast dataset to accelerate drug discovery and personalised treatment pathways. The company has pledged to uphold strict data privacy standards while leveraging the acquisition to fuel long-term R&D gains.

For pharma leaders, this signals a strategic pivot: control of genetic data is becoming a competitive edge in shaping next-gen therapeutics and prevention strategies.

Read the full story and discover what this could mean for your data strategy.